SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
0.888
-0.010 (-1.11%)
At close: Dec 20, 2024, 4:00 PM
0.950
+0.062 (6.98%)
After-hours: Dec 20, 2024, 7:47 PM EST
SLS Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Net Income | -32.28 | -37.34 | -41.3 | -20.7 | -16.76 | -19.29 | |
| Asset Writedown & Restructuring Costs | - | - | 10 | 5.7 | - | 2.83 | |
| Stock-Based Compensation | 1.69 | 2.09 | 1.73 | 1.01 | 0.58 | 0.57 | |
| Other Operating Activities | 0.54 | 0.49 | 0.13 | -4.42 | -0.11 | -0.65 | |
| Change in Accounts Payable | 0.3 | 2.3 | 1.21 | -2.51 | -0.84 | 0.01 | |
| Change in Unearned Revenue | - | - | - | -5.6 | 5.6 | - | |
| Change in Other Net Operating Assets | -3.32 | 1.04 | 4.43 | 0.5 | 1.11 | -1.12 | |
| Operating Cash Flow | -33.07 | -31.41 | -23.81 | -26.02 | -10.42 | -17.64 | |
| Sale (Purchase) of Intangibles | - | -5.5 | -4.5 | - | - | - | |
| Investing Cash Flow | - | -5.5 | -4.5 | - | - | - | |
| Issuance of Common Stock | 50.17 | 22.35 | 24.08 | 12.07 | 38.44 | 19.57 | |
| Repurchase of Common Stock | -0.03 | -0.03 | - | - | - | - | |
| Financing Cash Flow | 50.14 | 22.32 | 24.08 | 12.07 | 38.44 | 19.57 | |
| Net Cash Flow | 17.06 | -14.6 | -4.23 | -13.95 | 28.03 | 1.93 | |
| Free Cash Flow | -33.07 | -31.41 | -23.81 | -26.02 | -10.42 | -17.64 | |
| Free Cash Flow Margin | - | - | -2380.90% | -342.38% | -548.26% | - | |
| Free Cash Flow Per Share | -0.66 | -1.13 | -1.23 | -1.68 | -1.31 | -6.90 | |
| Levered Free Cash Flow | -21.81 | -29.64 | -11.87 | -18.69 | -3.6 | -11.55 | |
| Unlevered Free Cash Flow | -21.81 | -29.64 | -11.87 | -18.69 | -3.6 | -11.55 | |
| Change in Net Working Capital | 3 | 1.87 | -11.42 | 7.45 | -6.44 | 1.37 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.